Biotech Bubble Valuations From Sam Islay

Loading...
Loading...

OrbiMed Advisors managing partner Sam Isaly told CNBC that biotech could be volatile, however, the valuations were "sensible."

 

Isaly's top picks included:

 

ZIOPHARM Oncology Inc. ZIOP

 

Regeneron Pharmaceuticals Inc REGN

 

Actelion Ltd ALIOF

 

Molina Healthcare, Inc. MOH

Health Net, Inc. HNT

 

Isaly said that the performance of the industry had been "great" over the past 3 to 5 years and that explosive growth in new products was expected to drive biotech stocks higher.

 

The iShares NASDAQ Biotechnology Index (ETF) IBB had gained nearly 50 percent over the past 12 months and closed at $340.08 Wednesday, down 0.98 percent.

date
ticker
name
Price Target
Upside/Downside
Recommendation
Firm
Posted In: Analyst ColorCNBCAnalyst RatingsMediaCNBCOrbimed AdvisorsSam Isaly
We simplify the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!

Loading...